Table 1 Clinical characteristics of BC patients treated with adjuvant hypofractionated IMRT after BCS and known smoking status
From: Smoking increases breast toxicity despite adjuvant hypofractionated IMRT in early breast cancer
Whole cohort (n = 566) | Smokers (n = 177) | Nonsmokers (n = 389) | P value | |
|---|---|---|---|---|
Age at diagnosis, median [Q1; Q3] | 53.0 [47; 63] | 51 [46;59] | 54 [47;64] | 0.009 |
Menopause (n, %) | 288 (50.9) | 82 (49.7) | 206 (52.9) | 0.144 |
Breast laterality (n, %) | 0.184 | |||
Right | 292 (51.6) | 84 (47.5) | 208 (53.5) | |
Left | 274 (48.4) | 93 (52.5) | 181 (46.5) | |
Pathologic diagnosis (n, %) | 0.410 | |||
IDC | 444 (78.6) | 145 (81.9) | 299 (76.8) | |
DCIS | 73 (12.9) | 20 (11.3) | 53 (13.6) | |
ILC/Other | 48 (8.5) | 12 (6.8) | 36 (9.3) | |
Subtype (n, %) | 0.518 | |||
DCIS | 70 (12.4) | 20 (11.3) | 50 (12.9) | |
Luminal phenotype | ||||
Luminal A | 208 (36.8) | 66 (37.3) | 142 (36.5) | |
Luminal B HER2- | 109 (19.3) | 37 (20.9) | 72 (18.5) | |
Luminal B HER2+ | 42 (7.4) | 13 (7.3) | 29 (7.5) | |
Luminal A/B* | 75 (13.3) | 22 (12.4) | 53 (13.6) | |
Pure HER2+** | 10 (1.8) | 1 (0.6) | 9 (2.31) | |
Triple negative | 43 (7.6) | 17 (9.6) | 26 (6.7) | |
Unknown | 8 (1.4) | 1 (0.6) | 7 (1.8) | |
pT (n,%) | 0.119 | |||
T0 | 35 (6.5) | |||
Tx | 4 (0.7) | 0 (0.0) | 4 (1.0) | |
Tis | 72 (13.4) | 20 (11.3) | 52 (13.4) | |
T1a | 32 (5.9) | 6 (3.4) | 26 (6.7) | |
T1b | 129 (24.0) | 48 (27.1) | 81(20.8) | |
T1c | 221 (41.1) | 75 (42.4) | 146 (37.5) | |
T2 | 45 (8.4) | 11 (6.2) | 34 (8.7) | |
T3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
pN (n, %) | 0.222 | |||
N0/N0itc | 480 (91.3) | 146 (82.5) | 334 (85.8) | |
N1/N1mic | 46 (8.7) | 18 (10.2) | 28 (7.2) | |
≥N2 | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Chemotherapy (n,%) | 0.729 | |||
No | 368 (65.4) | 118 (66.6) | 250 (64.3) | |
Neoadjuvant | 66 (11.7) | 22 (12.4) | 44 (11.3) | |
Adjuvant | 129 (22.9) | 37 (20.9) | 92 (23.6) | |
Hormonotherapy (n, %) | 462 (85.2) | 148 (83.6) | 314 (80.7) | 0.718 |